Cyclooxygenase-2 is frequently overexpressed in human breast cancers

E. E. Half, C. J. Barnes, E. Chiang, N. Sneige, A. A. Sahin, Frank A Sinicrope

Research output: Contribution to journalArticle

Abstract

Background: Cyclooxgenase (COX) enzymes convert arachidonic acid to prostaglandins. Overexpression of the inducible COX isoform, COX-2, has been shown to play an important role in eolorectal tumorigenesis, however, its role in human breast cancer remains unknown. Evidence suggests that the COX-2 and c-erbB-2 pathways may be inter-related. Methods: We analyzed COX-2 and c-erbB-2 expression in formalin-fixed, parafin-embedded primary breast carcinomas (n=58). adjacent ductal carcinoma in situ (DCIS, n=14) and two cases of DCIS without invasive cancer. Histology included ductal (n=44), lobular (n=2), and other (n=7). Clinical stage was as follows: I (n=15). HA,B (n=24). Ill (n= 12). IV (n=1). ER and PR negativity was found in 21% and 46% of cancers, respectively. COX-2 and c-erbB-2 expression were detected by immunohistochemistry using highly specific monoclonal antibodies. The intensity and percentage of COX-2-stained cells was determined and a weight score was calculated. Membranous c-erbB-2 staining intensity was graded (10-3-). C-erbB-2 gene amplification was analyzed by FISH (n=20). The relationship between COX-2 and eerB-2 and clinicopathological variables was sought. Results: Cytoplasmic. granular COX-2 expression was detected in epithelial cells in 32 of 44 (72%) invasive breast cancers and in 14 of 16 (87%) eases of adjacent DCIS. Normal breast epithelium adjacent to cancer frequently had local staining of similar or decreased intensity relative to adjacent neoplastic epithelia. Rare peritumoral stromal cell COX-2 staining was observed. In 27 of 44 (62%) invasive cancers, COX-2 staining was diffuse, found in at least 50% of tumor cells. c-erbB-2 membranous staining (2 or 3+) was detected in 17 of 57 (30%) invasive cancers all but two cases were amplified. No significant correlation was found between COX-2 and c-erbB2 or clinicopathological variables. Conclusion: Our results indicate that COX-2 is frequently overexpressed in invasive breast cancers and adjacent DCIS. COX-2 inhibitors may be useful in the chemoprevention and therapy of human breast cancer.

Original languageEnglish (US)
Pages (from-to)296
Number of pages1
JournalBreast Cancer Research and Treatment
Volume69
Issue number3
StatePublished - 2001
Externally publishedYes

Fingerprint

Cyclooxygenase 2
Carcinoma, Intraductal, Noninfiltrating
Breast Neoplasms
Staining and Labeling
Neoplasms
Epithelium
erbB-2 Genes
Gene Amplification
Chemoprevention
Stromal Cells
Arachidonic Acid
Formaldehyde
Prostaglandins
Histology
Protein Isoforms
Carcinogenesis
Breast
Epithelial Cells
Immunohistochemistry
Monoclonal Antibodies

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Half, E. E., Barnes, C. J., Chiang, E., Sneige, N., Sahin, A. A., & Sinicrope, F. A. (2001). Cyclooxygenase-2 is frequently overexpressed in human breast cancers. Breast Cancer Research and Treatment, 69(3), 296.

Cyclooxygenase-2 is frequently overexpressed in human breast cancers. / Half, E. E.; Barnes, C. J.; Chiang, E.; Sneige, N.; Sahin, A. A.; Sinicrope, Frank A.

In: Breast Cancer Research and Treatment, Vol. 69, No. 3, 2001, p. 296.

Research output: Contribution to journalArticle

Half, EE, Barnes, CJ, Chiang, E, Sneige, N, Sahin, AA & Sinicrope, FA 2001, 'Cyclooxygenase-2 is frequently overexpressed in human breast cancers', Breast Cancer Research and Treatment, vol. 69, no. 3, pp. 296.
Half, E. E. ; Barnes, C. J. ; Chiang, E. ; Sneige, N. ; Sahin, A. A. ; Sinicrope, Frank A. / Cyclooxygenase-2 is frequently overexpressed in human breast cancers. In: Breast Cancer Research and Treatment. 2001 ; Vol. 69, No. 3. pp. 296.
@article{7ddfabd89809428aa3c2c5e2b74498b1,
title = "Cyclooxygenase-2 is frequently overexpressed in human breast cancers",
abstract = "Background: Cyclooxgenase (COX) enzymes convert arachidonic acid to prostaglandins. Overexpression of the inducible COX isoform, COX-2, has been shown to play an important role in eolorectal tumorigenesis, however, its role in human breast cancer remains unknown. Evidence suggests that the COX-2 and c-erbB-2 pathways may be inter-related. Methods: We analyzed COX-2 and c-erbB-2 expression in formalin-fixed, parafin-embedded primary breast carcinomas (n=58). adjacent ductal carcinoma in situ (DCIS, n=14) and two cases of DCIS without invasive cancer. Histology included ductal (n=44), lobular (n=2), and other (n=7). Clinical stage was as follows: I (n=15). HA,B (n=24). Ill (n= 12). IV (n=1). ER and PR negativity was found in 21{\%} and 46{\%} of cancers, respectively. COX-2 and c-erbB-2 expression were detected by immunohistochemistry using highly specific monoclonal antibodies. The intensity and percentage of COX-2-stained cells was determined and a weight score was calculated. Membranous c-erbB-2 staining intensity was graded (10-3-). C-erbB-2 gene amplification was analyzed by FISH (n=20). The relationship between COX-2 and eerB-2 and clinicopathological variables was sought. Results: Cytoplasmic. granular COX-2 expression was detected in epithelial cells in 32 of 44 (72{\%}) invasive breast cancers and in 14 of 16 (87{\%}) eases of adjacent DCIS. Normal breast epithelium adjacent to cancer frequently had local staining of similar or decreased intensity relative to adjacent neoplastic epithelia. Rare peritumoral stromal cell COX-2 staining was observed. In 27 of 44 (62{\%}) invasive cancers, COX-2 staining was diffuse, found in at least 50{\%} of tumor cells. c-erbB-2 membranous staining (2 or 3+) was detected in 17 of 57 (30{\%}) invasive cancers all but two cases were amplified. No significant correlation was found between COX-2 and c-erbB2 or clinicopathological variables. Conclusion: Our results indicate that COX-2 is frequently overexpressed in invasive breast cancers and adjacent DCIS. COX-2 inhibitors may be useful in the chemoprevention and therapy of human breast cancer.",
author = "Half, {E. E.} and Barnes, {C. J.} and E. Chiang and N. Sneige and Sahin, {A. A.} and Sinicrope, {Frank A}",
year = "2001",
language = "English (US)",
volume = "69",
pages = "296",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Cyclooxygenase-2 is frequently overexpressed in human breast cancers

AU - Half, E. E.

AU - Barnes, C. J.

AU - Chiang, E.

AU - Sneige, N.

AU - Sahin, A. A.

AU - Sinicrope, Frank A

PY - 2001

Y1 - 2001

N2 - Background: Cyclooxgenase (COX) enzymes convert arachidonic acid to prostaglandins. Overexpression of the inducible COX isoform, COX-2, has been shown to play an important role in eolorectal tumorigenesis, however, its role in human breast cancer remains unknown. Evidence suggests that the COX-2 and c-erbB-2 pathways may be inter-related. Methods: We analyzed COX-2 and c-erbB-2 expression in formalin-fixed, parafin-embedded primary breast carcinomas (n=58). adjacent ductal carcinoma in situ (DCIS, n=14) and two cases of DCIS without invasive cancer. Histology included ductal (n=44), lobular (n=2), and other (n=7). Clinical stage was as follows: I (n=15). HA,B (n=24). Ill (n= 12). IV (n=1). ER and PR negativity was found in 21% and 46% of cancers, respectively. COX-2 and c-erbB-2 expression were detected by immunohistochemistry using highly specific monoclonal antibodies. The intensity and percentage of COX-2-stained cells was determined and a weight score was calculated. Membranous c-erbB-2 staining intensity was graded (10-3-). C-erbB-2 gene amplification was analyzed by FISH (n=20). The relationship between COX-2 and eerB-2 and clinicopathological variables was sought. Results: Cytoplasmic. granular COX-2 expression was detected in epithelial cells in 32 of 44 (72%) invasive breast cancers and in 14 of 16 (87%) eases of adjacent DCIS. Normal breast epithelium adjacent to cancer frequently had local staining of similar or decreased intensity relative to adjacent neoplastic epithelia. Rare peritumoral stromal cell COX-2 staining was observed. In 27 of 44 (62%) invasive cancers, COX-2 staining was diffuse, found in at least 50% of tumor cells. c-erbB-2 membranous staining (2 or 3+) was detected in 17 of 57 (30%) invasive cancers all but two cases were amplified. No significant correlation was found between COX-2 and c-erbB2 or clinicopathological variables. Conclusion: Our results indicate that COX-2 is frequently overexpressed in invasive breast cancers and adjacent DCIS. COX-2 inhibitors may be useful in the chemoprevention and therapy of human breast cancer.

AB - Background: Cyclooxgenase (COX) enzymes convert arachidonic acid to prostaglandins. Overexpression of the inducible COX isoform, COX-2, has been shown to play an important role in eolorectal tumorigenesis, however, its role in human breast cancer remains unknown. Evidence suggests that the COX-2 and c-erbB-2 pathways may be inter-related. Methods: We analyzed COX-2 and c-erbB-2 expression in formalin-fixed, parafin-embedded primary breast carcinomas (n=58). adjacent ductal carcinoma in situ (DCIS, n=14) and two cases of DCIS without invasive cancer. Histology included ductal (n=44), lobular (n=2), and other (n=7). Clinical stage was as follows: I (n=15). HA,B (n=24). Ill (n= 12). IV (n=1). ER and PR negativity was found in 21% and 46% of cancers, respectively. COX-2 and c-erbB-2 expression were detected by immunohistochemistry using highly specific monoclonal antibodies. The intensity and percentage of COX-2-stained cells was determined and a weight score was calculated. Membranous c-erbB-2 staining intensity was graded (10-3-). C-erbB-2 gene amplification was analyzed by FISH (n=20). The relationship between COX-2 and eerB-2 and clinicopathological variables was sought. Results: Cytoplasmic. granular COX-2 expression was detected in epithelial cells in 32 of 44 (72%) invasive breast cancers and in 14 of 16 (87%) eases of adjacent DCIS. Normal breast epithelium adjacent to cancer frequently had local staining of similar or decreased intensity relative to adjacent neoplastic epithelia. Rare peritumoral stromal cell COX-2 staining was observed. In 27 of 44 (62%) invasive cancers, COX-2 staining was diffuse, found in at least 50% of tumor cells. c-erbB-2 membranous staining (2 or 3+) was detected in 17 of 57 (30%) invasive cancers all but two cases were amplified. No significant correlation was found between COX-2 and c-erbB2 or clinicopathological variables. Conclusion: Our results indicate that COX-2 is frequently overexpressed in invasive breast cancers and adjacent DCIS. COX-2 inhibitors may be useful in the chemoprevention and therapy of human breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=33749110220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749110220&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33749110220

VL - 69

SP - 296

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -